“The good physician treats the disease, the great physician treats the patient…”
William Osler
Myeloid white blood cells can develop a surface growth receptor protein known as BCR/ABL1. This receptor target interferes with the regulation of white blood cell production and leads a type of leukaemia referred to as CML. Use a quantitative PCR test for BCR/ABL1 and you can count the number of leukaemic cells in the body. Asciminib (the cute little orange worms) is an allosteric inhibitor of BCR/ABL1. This drug binds to the myristoyl pocket of the receptor protein, enabling re establishment of auto inhibition for patients with CML. A lot of the initial clinic trials of Asciminib have been conducted by researchers and clinicians here in Adelaide. I am about to benefit from that that those efforts and discover how the theory works in practice. #SAHMRIresearchers #letsmakelemonade
Pen Paint and Scalpel 